Sponsor content

Collaborative Research and Licensing Opportunity: Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use

Llama-derived single chain antibody fragments (also called VHH) are small, recombinant monoclonal antibodies of 15 kDa (“nanobodies”) with several advantages over conventional antibodies. The antibodies that were derived from llamas showed strong neutralizing activity against Norovirus in in vitro assays.

Vaccines and therapies to prevent and treat Norovirus infections are not available, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group settings, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This application claims isolated VHH monoclonal antibodies that specifically bind to a Norovirus polypeptide. Llama-derived single chain antibody fragments (also called VHH) are small, recombinant monoclonal antibodies of 15 kDa (“nanobodies”) with several advantages over conventional antibodies. The antibodies that were derived from llamas showed strong neutralizing activity against Norovirus in in vitro assays. These nanobodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections, and may be potentially utilized in vaccine research.

Potential Commercial Applications:

  • Therapeutics
  • Diagnostics
  • Vaccine research

Advantages:

  • Ease of manufacture
  • Potent neutralizing activity
  • Potential cross-reactivity
  • Low-cost therapeutics/immunoprophylaxis

Publications:

Garaicoechea L. et al., “Llama nanoantibodies with therapeutic potential
against human norovirus diarrhea,” PLoS One. 2015 Aug 12;10(8):e0133665.
doi:10.1371/journal.pone.0133665. eCollection 2015. [PMID 26267898].

Intellectual Property:

HHS Reference No. E-136-2013/0:

U.S. Provisional Application No. 61/821,354; PCT Application No. PCT/US2014/037520; European Application No. 14727696.8; U.S. Application No. 14/889,774; Argentine Application No. 20140101882.

Collaborative Research Opportunity:
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic, diagnostic or vaccine for Norovirus infections.

Contact:

Please contact Peter Soukas, J.D., 301-594-8730; peter.soukas@nih.gov.


Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.